Pipeline
Pipeline
CLZ001 & CLZ002
First-in-class anti-PROX1 antibody protein (CLZ001) and gene (CLZ002) therapies
CLZ001 & CLZ002
First-in-class anti-PROX1 antibody protein (CLZ001) and gene (CLZ002) therapies
CLZ001 is a high-affinity anti-PROX1 antibody designed to trigger endogenous retinal regeneration.
It targets extracellular PROX1 proteins,
a key inhibitory factor that suppresses tissue repair and regeneration.
By neutralizing extracellular PROX1, CLZ001 reactivates dormant Müller glia regenerative pathways and offers
a novel approach to restoring vision.
CLZ002 is an AAV gene therapy
that delivers a gene encoding
an anti-PROX1 antibody to the diseased retina when CLZ001 is not applicable.
PROX 1
Target Molecule
AMD / RP
Lead Programs
Expanding Target Diseases
Future
PROX 1
Target Molecule
AMD / RP
Lead Programs
Expanding Target Diseases
Future
PIPELINE
Homeoprotein-Based Therapeutic Pipeline
Advancing innovative therapies through two complementary homeoprotein strategies.
CLZ001 Wet-AMD
Lead Optimization
CLZ002 RP
Preclinical
CLZ003 Dry-AMD
Target Validation
CLZ004 Alzheimer’s Disease
Target Validation
PIPELINE
Homeoprotein-Based Therapeutic Pipeline
Advancing innovative therapies through two complementary homeoprotein strategies.
CLZ001 Wet-AMD
Lead Optimization
CLZ002 RP
Preclinical
CLZ003 Dry-AMD
Target Validation
CLZ004 Alzheimer’s Disease
Target Validation
CREATING A NEW THERAPEUTIC
PARADIGM FOR DEGENERATIVE DISEASES
Tissue Regeneration
By Homeoprotein Targeting Therapies.
Contact
Celliaz Co., Ltd.
205 Jinri Hall, KAIST Munji Campus
193 Munji-ro, Yuseong-gu
Daejeon 34051, Republic of Korea
Phone
+82-42-716-4061
info@celliaz.com
Retinal Regeneration
Through Homeoprotein Science
Advancing retinal regeneration
through homeoprotein-based
therapeutics.
Contact
Celliaz Co., Ltd.
205 Jinri Hall, KAIST Munji Campus
193 Munji-ro, Yuseong-gu
Daejeon 34051, Republic of Korea
Phone
+82-42-716-4061
info@celliaz.com